ClinicalTrials.gg

Program

milsaperidone

Also written as “VHX-896 and iloperidone”, “Iloperidone and VHX-896” and “Milsaperidone”.

Its studies are mostly in Depressive Disorder, Major · Schizophrenia, led by Vanda Pharmaceuticals.

Furthest: phase 3, since Feb 11, 20254 company-led studies, 1 open or runningNext primary completion: Mar 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticals41 open or runningphase 3since Feb 11, 2025Jul 9, 2021Mar 2028phase 3 · NCT06830044

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 9, 2021First study: phase 1 study in HealthyFirst studyNCT04969211 · 25 enrolled · United States
  2. Jul 2, 2024Phase 1 study in SchizophreniaNCT06494397 · 26 enrolled · United States
  3. Jan 27, 2025Phase 1 study in HealthyNCT06803290 · 24 enrolled · United States
  4. Feb 11, 2025Phase 3 study in Depressive Disorder, MajorNCT06830044 · 500 planned · United States, Bulgaria, Czechia and more

Ahead

  1. Mar 2028Primary completion: phase 3 study in Depressive Disorder, MajorNCT06830044

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06830044Depressive Disorder, Major · United States, Bulgaria, Czechia and more3RecruitingMar 2028500
NCT06803290Healthy · United States1CompletedDec 27, 202224
NCT06494397Schizophrenia · United States1CompletedOct 24, 202426
NCT04969211Healthy · United States1CompletedOct 13, 202125

How it is read

Names in the registry

  • “VHX-896 and iloperidone”, 2 entries
  • “Iloperidone and VHX-896”, 2 entries
  • “Milsaperidone”, 1 entry
  • “VHX-896”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.